Loxosceles Immune F(Ab)2 (Reclusmyn)

✓ Approved

Instituto Bioclon · Polyclonal Antibodies · Polyclonal Antibodies

What is Loxosceles Immune F(Ab)2?

Loxosceles Immune F(Ab)2 is a polyclonal antibodies developed by Instituto Bioclon. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Names	Reclusmyn
Company	Instituto Bioclon
Drug Class	Polyclonal Antibodies, Antibody
Route	Injectable (Others), Intravenous (IV)
Status	Approved

Sources: ClinicalTrials.gov, Instituto Bioclon

Therapeutic Indications

Loxosceles Immune F(Ab)2 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Injury, poisoning and procedural complications	Venom poisoning	✓ Approved

Related Research Articles

PubMedEMBO molecular medicine2026-08-30

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

Liu Lijie L, Yan Mengrong M, Liang Ruoxu R, Wu Qingxin Q et al.

Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.

PMID 42668284

Read full article →

PubMedMarine life science & technology2026-08-30

Inhibitory effect of gut microbiota-fermented trisaccharide GuFGa (Glc-Fuc-Gal) on Campylobacter jejuni: insights from transcriptomic and metabolomic analyses.

Ren Xinmiao X, Li Shuang S, Wang Changyun C, Secundo Francesco F et al.

Fucose-rich carbohydrates, such as 2'-fucosyllactose and fucoidan, are recognized as anti-infective components that protect the host from pathogens. In this study, the response of the common enteric pathogen Campylobacter jejuni to a specific fucose-containing trisaccharide (GuFGa, β-D-Glcp-(1 → 4)-[β-D-Galp-(1 → 3)]-α-ʟ-Fucp) fermented with human fecal microbiota was investigated using metabolomic and transcriptomic analyses. The protective effect of GuFGa-derived microbial metabolites against C. jejuni was assessed in vitro using a cell-based model. No directly inhibitory effect of GuFGa was observed with the growth of C. jejuni during single-strain cultivation. However, the supernatant of GuFGa fermented with human fecal microbiota (F-GuFGa) reduced the relative abundance of C. jejuni by tenfold within the microbial community. Transcriptome data showed that 128 differentially expressed genes of C. jejuni induced by F-GuFGa treatment were mainly enriched in oxidative phosphorylation and bacterial secretion systems (type IV). Fecal fermentation of GuFGa altered 452 differentially abundant metabolites, which were mainly enriched in phenylalanine and tryptophan metabolism. Correlation analysis indicated that the expression of type IV secretion system genes was significantly negatively correlated with the abundance of phenylacetic acid (PAA) and D-3-phenyllactic acid (D-PLA) (P < 0.05). Adhesion of C. jejuni to Caco-2 cells was reduced by treatment with F-GuFGa, PAA and D-PLA, with the highest inhibition rate observed for F-GuFGa (44.4%), followed by D-PLA (33.3%). This study provides a new perspective for developing GuFGa and similarly fucose-rich oligosaccharides as innovative dietary interventions to inhibit bacterial infections and improve gut health. The online version contains supplementary material available at https://doi.org/10.1007/s42995-026-00394-1.

PMID 42668736

Read full article →

PubMedDrug delivery and translational research2026-08-30

Biodegradable furylacryloyl-modified hyaluronan: in vivo evaluation and its use as a nanofibrous drug delivery system.

Brtková Barbora B, Bártová Tereza T, Piskláková Lenka L, Šimek Matěj M et al.

Furylacryloyl-modified hyaluronan (F-HA) has emerged as an appropriate material for the fabrication of UV-crosslinkable, water-stable nanofibrous scaffolds with preserved porosity. However, the safety profile and in vivo applicability of F-HA have not yet been established. In this study, we present biological assessment of F-HA, including biodegradation studies and its first in vivo evaluation in C57BL/6J mice following both intravenous and intraperitoneal administration. The results demonstrate good tolerability under the tested conditions and confirm biodegradability. Additionally, we confirm the ability of composite nanofibers consisting of F-HA with established nanofiber-forming polymers, to incorporate active pharmaceutical ingredients (API), while retaining their porous structure and favorable mechanical properties. Importantly, the incorporation of F-HA alters the release profile of embedded API. Using octenidine dihydrochloride (OCT) as a model compound, we demonstrate sustained release from F-HA/lauroyl hyaluronan (L-HA) nanofibrous scaffolds in biologically relevant protein-containing media, while retaining its structural integrity, thus supporting its suitability for biomedical applications. These findings highlight the potential of F-HA as a versatile platform for the development of advanced nanofibrous biomaterials with translational relevance in topical wound healing and drug delivery.

PMID 42668347

Read full article →

PubMedAging2026-08-30

Human-relevant Ptpn6 mutation alters immune and hepatic functions during aging.

Labrada Beisy Laborit BL, Kumar Amit A, Kolnohuz Alona A, Pineault Marie M et al.

Src homology region 2-containing phosphatase 1 (SHP-1), encoded by the protein tyrosine phosphatase non-receptor type 6 (PTPN6), regulates immune and metabolic signaling pathways. Although its functions in immune cells and insulin-responsive tissues are separately established, its integrative function in immunometabolic regulation remains unclear. A damaging variant in the PTPN6 gene (Ala455Thr) was discovered in a French-Canadian family and found to be the cause of early-onset emphysema. Using mice carrying this whole-body human-relevant mutation, we studied immunometabolic phenotypes across aging. Old mutant mice showed decreased body, liver and adipose tissue weights, improved glucose tolerance, and enhanced hepatic insulin sensitivity. Despite improved metabolic parameters, aged mutant mice developed liver abnormalities, including increased fibrosis and aberrant immune cell infiltration. Transcriptomic and histological analyses revealed an age-associated accumulation of intrahepatic B lymphocytes and macrophages, accompanied by increased SHP-1 protein levels and activation of Signal transducer and activator of transcription 3 (STAT3) signaling. Experiments in primary hepatocytes and old hepatocyte-specific Ptpn6 knockout mice suggest that these alterations are driven by immune rather than intrinsic hepatocyte mechanisms. These findings identify SHP-1 as a critical modulator of liver immune homeostasis during aging and demonstrate that immune cell infiltration contributes to age-related hepatic remodeling under SHP-1 deficiency.

PMID 42669491

Read full article →

PubMedMedical science monitor : international medical journal of experimental and clinical research2026-08-30

Postoperative Sexual Quality of Life and Associated Factors After Loop Electrosurgical Excision Procedure Versus Cold Knife Conization in 185 Sexually Active Women With Preinvasive Cervical Lesions.

Ozkaya Ucar Yesim Y, Turan Taner T

BACKGROUND Excisional treatment is widely used for preinvasive cervical lesions, but its effect on postoperative sexual quality of life remains uncertain. This study aimed to compare postoperative Sexual Quality of Life-Female (SQoL-F) scores and examine associated factors in women treated with cold knife conization or loop electrosurgical excision procedure (LEEP). MATERIAL AND METHODS This study included 185 sexually active women treated with cold knife conization (n=99) or LEEP (n=86) for histologically confirmed preinvasive cervical lesions during 2022-2024 and assessed at least 6 months postoperatively. The primary outcome was the total score on the validated 18-item SQoL-F questionnaire, transformed to a 0-100 scale. Between-group comparisons and multivariable linear regression with heteroskedasticity-consistent type 3 robust standard errors were performed. RESULTS Mean SQoL-F scores were similar after conization and LEEP (48.74±14.76 vs 49.70±12.76; P=0.640; Hedges' g=-0.07). In multivariable analysis, surgical technique was not associated with SQoL-F scores (ß=4.03; 95% confidence interval, -1.13 to 9.20; P=0.125). Age, marital status, weekly sexual frequency, family structure, preoperative sexual life perception, postoperative expectation, and body perception were associated with SQoL-F scores. The model explained 23.7% of the variance (R²=0.237), and internal consistency was high (Cronbach's alpha=0.886). CONCLUSIONS SQoL-F scores did not differ significantly between women who underwent cold knife conization and those who underwent LEEP. Several demographic, psychosocial, and interpersonal factors, rather than surgical technique, were associated with SQoL-F scores, although the cross-sectional design precludes causal inference.

PMID 42668418

Read full article →

PubMedFood & function2026-08-30

Abelmoschus manihot (L.) leaf flavonoids (AMLF) restore cyclophosphamide-induced immunosuppression in mice via gut microbiota and serum metabolomics modulation.

Yang Shengnan S, Jin Jiahui J, Zhao Dou D, Cai Mengquan M et al.

Immune homeostasis serves as the foundation for disease prevention and the cornerstone for ensuring human health. The effects of Abelmoschus manihot (L.) leaf flavonoids (AMLF) on restoring immune function were investigated in a cyclophosphamide (CTX)-induced immunosuppressed mouse model. The underlying repair mechanisms were explored by an integrative analysis of intestinal microbiomics and serum metabolomics. The results demonstrated that AMLF markedly elevated the spleen and thymus indices, promoted the proliferation of splenic lymphocytes in the presence of concanavalin A (ConA) or lipopolysaccharide (LPS) and CD4+ and CD8+ T lymphocyte subsets, and concomitantly enhanced the serum levels of key immunomodulatory cytokines, including interleukin-1β (IL-1β), interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α), and the antibody immunoglobulin G (IgG). In addition, AMLF treatment effectively mitigated CTX-induced histopathological injuries to immune organs and the colon. AMLF were also found to protect the liver by regulating antioxidant enzyme activities. Furthermore, AMLF markedly improved the intestinal microbial community structure, promoted the enrichment of beneficial bacteria (Lactobacillaceae and Prevotellaceae), inhibited pathogenic bacteria (Muribaculaceae and Desulfovibrionaceae), and increased the content of short-chain fatty acids (SCFAs). Serum metabolomic analysis showed that AMLF upregulated the levels of leukotrienes, S-(PGA1)-glutathione and prostaglandin E2. Correlation analysis identified g_Alistipes, g_norank_f_Muribaculaceae, and g_Kurthia as potential microbiota strongly associated with the restoration of immune and metabolic homeostasis after AMLF treatment. These findings support the dual potential of AMLF in functional foods and as immunomodulatory adjuvants.

PMID 42669286

Read full article →

+9996 more articles available with a free account

Loxosceles Immune F(Ab)2 (Reclusmyn)

What is Loxosceles Immune F(Ab)2?

Drug Profile

Therapeutic Indications

Related Research Articles

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

Inhibitory effect of gut microbiota-fermented trisaccharide GuFGa (Glc-Fuc-Gal) on Campylobacter jejuni: insights from transcriptomic and metabolomic analyses.

Biodegradable furylacryloyl-modified hyaluronan: in vivo evaluation and its use as a nanofibrous drug delivery system.

Human-relevant Ptpn6 mutation alters immune and hepatic functions during aging.

Postoperative Sexual Quality of Life and Associated Factors After Loop Electrosurgical Excision Procedure Versus Cold Knife Conization in 185 Sexually Active Women With Preinvasive Cervical Lesions.

Abelmoschus manihot (L.) leaf flavonoids (AMLF) restore cyclophosphamide-induced immunosuppression in mice via gut microbiota and serum metabolomics modulation.

Ask about Loxosceles Immune F(Ab)2